GIP
PVLA

Granite Investment Partners’s Palvella Therapeutics PVLA Stock Holding History

Granite Investment Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-539
Closed -$147K – 348
2019
Q3 		$147K Sell
539
-341
-39% -$132K 0.01% 332
2019
Q2 		$331K Sell
880
-774
-47% -$231K 0.02% 302
2019
Q1 		$443K Buy
+1,654
New +$393K 0.03% 307

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Granite Investment Partners's PVLA Position: Q4 2019 in Review

Granite Investment Partners sold out of Palvella Therapeutics (PVLA) in Q4 2019, closing a stake of 539 shares — an estimated $147K sold.

Granite Investment Partners first reported a position in PVLA in Q1 2019 and held it in 3 quarters. The position peaked at $443K in Q1 2019. 97 funds tracked by Wall St. Rank hold PVLA as of Q4 2019.

  • Granite Investment Partners reported no remaining Palvella Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Granite Investment Partners sold 539 Palvella Therapeutics shares in Q4 2019, an estimated $147K.
  • Granite Investment Partners first reported a position in Palvella Therapeutics in Q1 2019 and held it in 3 quarters.
  • Granite Investment Partners's Palvella Therapeutics position peaked at $443K in Q1 2019.
  • 97 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2019.

Based on Granite Investment Partners's 13F filing for Q4 2019, filed 10 Feb 2020.